

# Affibody

[View the current Affibody Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/17988-Affibody.html)

(<http://www.bioportfolio.com/biocorporate/17988-Affibody.html>)

## Contact Details:

**Voltavägen 13, floor 5  
Bromma**

Tel: 46 (0) 8 598 838 00

Fax: 46 (0) 8 598 838 01

Email: [reception@affibody.com](mailto:reception@affibody.com)

**SE-168 69  
Sweden**

Affibody has developed a unique pipeline of affinity ligands in oncology, covering the entire value chain from research reagents to molecular imaging agents and targeted therapeutics. The company has obtained outstanding clinical molecular imaging results and promising targeted therapeutics pre-clinical results. Affibody expects to launch one molecular imaging agent per year from 2007 and to file one targeted therapeutics IND every second year.

## Recent Publications by Affibody:



- [Engineering of a femtomolar affinity binding protein to human serum albumin.](#)  
*We describe the development of a novel serum albumin binding protein...* 15th August, 2009  
Affibody AB, Voltavägen 13, SE-161 02 Bromma.- Protein Eng Des Sel. 2008 Aug;21(8):515-27. Epub 2008 May 22. ([DOI Direct Link](#))
- [Evaluation of the Radiocobalt-Labeled \[MMA-DOTA-Cys\(61\)\]-Z \(HER2:2395\)-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors.](#)  
*PURPOSE: Imaging using positron emission tomography (PET) in the field of...* 27th June, 2009  
Affibody AB, Bromma, Sweden.- Mol Imaging Biol. 2009 Jun 26. ([DOI Direct Link](#))
- [On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.](#)  
*Human epidermal growth factor receptor type 2 (HER2) is a tyrosine kinase,...* 6th June, 2009  
Affibody AB, Bromma, Sweden.- J Nucl Med. 2009 Mar;50(3):417-25. Epub 2009 Feb 17. ([DOI Direct Link](#))
- [The influence of Bz-DOTA and CHX-A"-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for \(114m\)In-mediated targeting therapy.](#)  
*PURPOSE: Affibody molecules represent a novel class of high-affinity...* 12th May, 2009

- Affibody- Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1460-8. Epub 2009 May 9. ([DOI Direct Link](#))
- [Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.](#)  
*Affibody molecules are a novel class of targeting proteins, demonstrating...* 17th December, 2008  
 Affibody AB, Bromma, Sweden.- Cancer Biother Radiopharm. 2008 Aug;23(4):435-42. ([DOI Direct Link](#))
  - [Evaluation of \[\(111/114m\)In\]CHX-A"-DTPA-ZHER2:342, an affibody ligand conjugate for targeting of HER2-expressing malignant tumors.](#)  
*AIM: Radionuclide imaging of the HER2 receptor, which is a target for...* 28th May, 2008  
 - Q J Nucl Med Mol Imaging. 2007 Dec;51(4):314-23. Epub 2007 May 1.
  - [Update: affibody molecules for molecular imaging and therapy for cancer.](#)  
*Affibody molecules are scaffold proteins, having a common frame of amino...* 16th January, 2008  
 - Cancer Biother Radiopharm. 2007 Oct;22(5):573-84. ([DOI Direct Link](#))
  - [Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy.](#)  
*Molecular imaging shows promise as a useful tool to aid drug discovery and...* 3rd May, 2007  
 Affibody AB, Box 20137, Voltav 13, SE-161 02 Bromma, Sweden.- Curr Opin Drug Discov Devel. 2007 Mar;10(2):167-75.
  - [Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.](#)  
*A radiolabeled anti-HER2 Affibody molecule (Z(HER2:342)) targets...* 20th April, 2007  
 Affibody AB, Bromma, Sweden.- Cancer Res. 2007 Mar 15;67(6):2773-82. ([DOI Direct Link](#))
  - [Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.](#)  
*The Affibody molecule Z(HER2:342-pep2), site-specifically and...* 14th April, 2007  
 Affibody AB, Voltavagen 13, SE-16102 Bromma, Sweden.- Cancer Res. 2007 Mar 1;67(5):2178-86. ([DOI Direct Link](#))
  - [Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy.](#)  
*Targeting radionuclide imaging of tumor-associated antigens may help to...* 5th April, 2007  
 Affibody AB, Box 20137, SE-161 02 Bromma, Sweden.- Expert Opin Biol Ther. 2007 Apr;7(4):555-68. ([DOI Direct Link](#))
  - [Tumor imaging using a picomolar affinity HER2 binding affibody molecule.](#)  
*The detection of cell-bound proteins that are produced due to aberrant...* 8th June, 2006  
 Affibody AB, Bromma, Sweden.- Cancer Res. 2006 Apr 15;66(8):4339-48. ([DOI Direct Link](#))
  - [Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.](#)  
*In vivo diagnosis with cancer-specific targeting agents that have optimal...* 28th April, 2006  
 Affibody AB, Bromma, Sweden.- J Nucl Med. 2006 Mar;47(3):512-9.

## Press Releases on Affibody:

[Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment](#)

26th October, 2009 Reportlinker

-- A focus on "engineered" antibodies  
 Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing

[The Board of International  
Biotechnology Trust Plc  
\("IBT"\) today](#)

1st May, 2005

International Biotechnology  
Trust

*The Board of International  
Biotechnology Trust Plc  
("IBT") today announces its  
unaudited Annual Results  
for the twelve months  
ended 31 August 2005  
Summary • Net asset value  
per share rose*

#### Affibody Patents:



- 6955877- [In vitro selection and optional identification of polypeptides using solid support carriers](#)
- 6831161- [Method of affinity separation and ligands for use therein](#)
- 6267964- [Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

